Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Buy” from Analysts

Replimune Group, Inc. (NASDAQ:REPLGet Rating) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $48.33.

Several research analysts have commented on the company. BMO Capital Markets reduced their price objective on Replimune Group from $51.00 to $30.00 and set an “outperform” rating on the stock in a report on Friday, March 18th. JPMorgan Chase & Co. dropped their target price on Replimune Group from $47.00 to $39.00 and set an “overweight” rating on the stock in a research report on Monday, April 4th. Finally, Zacks Investment Research raised Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday.

In other news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of the firm’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $15.42, for a total value of $254,430.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 40.30% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Replimune Group by 2.3% during the 4th quarter. BlackRock Inc. now owns 2,137,118 shares of the company’s stock valued at $57,915,000 after buying an additional 48,263 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Replimune Group by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 1,625,758 shares of the company’s stock valued at $27,606,000 after buying an additional 81,845 shares during the last quarter. Emerald Advisers LLC increased its stake in shares of Replimune Group by 14.6% in the 1st quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company’s stock valued at $19,256,000 after purchasing an additional 144,054 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in shares of Replimune Group by 5.8% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,075,464 shares of the company’s stock valued at $29,145,000 after purchasing an additional 58,527 shares in the last quarter. Finally, BVF Inc. IL increased its stake in shares of Replimune Group by 0.8% in the 3rd quarter. BVF Inc. IL now owns 926,529 shares of the company’s stock valued at $27,462,000 after purchasing an additional 7,601 shares in the last quarter. Institutional investors own 75.42% of the company’s stock.

Shares of NASDAQ REPL traded up $0.77 during midday trading on Friday, hitting $14.83. The company’s stock had a trading volume of 248,852 shares, compared to its average volume of 401,366. The company has a current ratio of 23.39, a quick ratio of 23.39 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $16.87 and its two-hundred day moving average is $22.10. Replimune Group has a 12-month low of $13.05 and a 12-month high of $40.22. The firm has a market cap of $700.12 million, a P/E ratio of -7.16 and a beta of 2.29.

About Replimune Group (Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Further Reading

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.